Taishan financial reporter Hu Mingzheng
With the arrival of 2024, Lunan Pharmaceutical Group ushered in a series of exciting news, marking the group's remarkable achievements in innovative drug research and development and market performance. Recently, the Group's "anti-hair loss miracle drug" minoxidil liniment has been approved, and the new specifications of isosorbide mononitrate sustained-release tablets have also been recognized by the FDA.
Back in 2023, a total of 12 new products of Lunan Pharmaceutical Group have been approved, and 9 products in the eighth and ninth batches of national drug procurement have successfully won the bid. It is worth mentioning that the cumulative sales of the group's first marketed biodrug, pegylated human granulocyte stimulating factor injection, have exceeded 1400 million RMB. At present, the Group is striving to promote the launch of 52 new products, of which 9 blockbuster new drugs have entered the clinical stage above Phase I. 
*: Minenet.
In the past three years, Lunan Pharmaceutical Group has successfully launched 3 first generic drugs, and the cumulative sales of its first biological drug have exceeded 100 million yuan. A number of subsidiaries of the group, including Lunan Houpu Pharmaceutical, Lunan Bet Pharmaceutical and Shandong New Era Pharmaceutical, have made remarkable achievements in their respective fields. For example, Shandong New Era Pharmaceutical's strength in the generic drug market should not be underestimated, and it has successfully obtained the first domestic generic qualification for a number of products.
In the national drug procurement in 2023, Lunan Pharmaceutical Group performed outstandingly, with a total of 17 products successfully winning the bid. In addition, Shandong New Era Pharmaceutical's gemcitabine hydrochloride for injection passed the consistency evaluation, bringing the number of products that the group has evaluated to 61.
Lunan Pharmaceutical Group is also actively expanding its product line, and currently has 51 high-end generic drugs and 1 new biopharmaceutical product in the approval process. The Group's layout in the field of biologics is also accelerating, for example, its first insulin preparation, insulin glargine injection, has been approved, and a new drug application for rituximab injection has been submitted.
The research and development of innovative drugs is another major focus of Lunan Pharmaceutical Group. Up to now, the Group has applied for clinical trials of 20 new drugs, covering biologic, chemical and proprietary Chinese medicines. Among them, a number of new biologics Class 1 drugs are advancing rapidly, which is expected to bring more market opportunities to the Group.
Looking forward to 2024, Lunan Pharmaceutical Group is ready to meet new challenges, and looks forward to achieving better results in innovative drug research and development and market competition, and continuing to consolidate and enhance its leading position in the pharmaceutical industry.